



DT05 PCT/PTO 30 SEP 2002 PCT/Box/eq #7

<b>OBLON</b>
<b>SPIVAK</b>
<b>McCLELLAND</b>
<b>MAIER</b>
<b>&amp;</b>
<b>NEUSTADT</b>
<b>P.C.</b>

Docket No.: 217365US0PCT

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

ATTORNEYS AT LAW

RE: Application Serial No.: 09/926,778

Applicants: Selim ARACTINGI, et al.

Filing Date: December 18, 2001

For: COMPOSITIONS CONTAINING SOLUBLE FORMS  
OF HLA-G IN THE TREATMENT OF  
INFLAMMATORY SKIN PATHOLOGIES

SIR:

Attached hereto for filing are the following papers:

**Response to Notice (2 pp.)**

**Return Copy - Notification of Defective Response**

**Date-Stamped Filing Receipt dated July 1, 2002**

**Preliminary Amendment and Statement w/Marked-Up Copy Filed July 1, 2002**

**Sequence Listing Paper (1 page) Filed July 1, 2002**

**Sequence Listing Computer Readable Form (CRF) Diskette as Filed July 1, 2002**

Our check in the amount of **\$0.00** is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618



22850

(703) 413-3000 (phone)  
(703) 413-2220 (fax)

James J. Kelly, Ph.D.

Registration No. 41,504



UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents, Box PCT  
 United States Patent and Trademark Office  
 Washington, D.C. 20231  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/926,778	Selim Aractingi	217365US0PCT

INTERNATIONAL APPLICATION NO.	
PCT/FR00/01670	
I.A. FILING DATE	PRIORITY DATE
06/16/2000	06/18/1999

 22850  
 OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC  
 FOURTH FLOOR  
 1755 JEFFERSON DAVIS HIGHWAY  
 ARLINGTON, VA 22202

CONFIRMATION NO. 1465

371 FORMALITIES LETTER



\*OC000000008713624\*

Date Mailed: 08/30/2002

## NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Request for Immediate Examination

RECEIVED: 9-3-02OBLON, SPIVAK, McCLELLAND  
MAIER & NEUSTADT, P.C.

DOCKETING DEPT.

Initials/Date Docketed: ASH 9-3-02Type of Resp(s): Reg. List Reg.Due Date(s): 9-30-02

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
  - APPLICANT MUST PROVIDE:
    - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

KAREN R MCLEAN

Telephone: (703) 308-9117

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/926,778	PCT/FR00/01670	217365US0PCT



Dept.: CHEMICAL

By: NFO:JK:TWB:aps

OSMM&N File No. 217365US0PCT


Serial No. 09/926,778

In the matter of the Application of: Selim ARACTINGI, et al.

For: COMPOSITIONS CONTAINING SOLUBLE FORMS OF HLA-G  
FOR TREATING INFLAMMATORY SKIN PATHOLOGIES


The following has been received in the U.S. Patent Office on the date stamped hereon:

- ☐ pp. Specification      Claims/Formal Drawings      Sheets  
and      pages Application Data Sheet
- ☒ Combined Declaration, Petition & Power of Attorney      4 pages (executed)
- ☒ Filing of Declaration Under 37 CFR 1.53(f)
- ☐ Utility Patent Application Transmittal      ☐ CPA
- ☐ Notice of Priority      ☐ Priority Doc
- ☒ Check for      \$920.00      ☒ Dep. Acct. Order Form
- ☐ Fee Transmittal Form
- ☐ Assignment/PTO 1595 pages:
- ☐ Letter to Official Draftsman
- ☐ Letter Requesting Approval of Drawing Changes
- ☐ Formal Drawings      sheets      ☐ Formal
- ☒ PTO Cover Letter
- ☒ Preliminary Amendment and Statement w/Marked-Up Copy (4 pp.)
- ☐ Information Disclosure Statement      ☐ PTO-1449
- ☐ Cited References
- ☐ Search Report
- ☐ Statement of Relevancy      ☐ Cited Pending Applications
- ☐ IDS/Related/List of Related Cases
- ☐ Restriction Response      ☐ Election Response
- ☐ Rule 132 Declaration
- ☒ Request for Extension of Time (three months)
- ☒ Sequence Listing Computer Readable Form (CRF) Diskette
- ☒ Sequence Listing Paper (1 page)
- ☐



Due Date: June 29, 2002

217365US-0PCT



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :  
SELIM ARACTINGI ET AL : ATTN: APPLICATION DIVISION  
SERIAL NO: 09/926,778 :  
FILED: DECEMBER 18, 2001 :  
FOR: COMPOSITIONS CONTAINING :  
SOLUBLE FORMS OF HLA-G FOR TREATING  
INFLAMMATORY SKIN PATHOLOGIES

RESPONSE TO NOTICE

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Applicants respectfully submit herewith, copies of the Preliminary Amendment and Statement, Sequence Listing, Computer Readable Sequence Listing, and the date-stamped filing receipt demonstrating the timely filing of the same on July 1, 2002, in response to the Notice dated August 30, 2002, in the above-identified Application.


The Office contends that Applicants have not complied with the Sequence Listing requirements set out in 37 CFR §1.821-1.825 in the above-mentioned Notice. Applicants respectfully request withdrawal of this Notice based on Applicants' timely filing of the Preliminary Amendment and Statement, Sequence Listing, Computer Readable Sequence Listing on July 1, 2002, in response to the Notice dated January 29, 2002. A copy of the date-stamped filing receipt is provided for the Office's convenience, which demonstrate the timely filing of the same.

Applicants attempted to contact Ms. Karen McLean at the USPTO in order to obtain information regarding this Notice dated August 30, 2002, however, Applicants attempts were unsuccessful. Therefore, Applicants provide herewith a copy of the Computer Readable Sequence Listing filed July 1, 2002. Contents of the paper copy of the Substitute Sequence Listing filed July 1, 2002, and the computer-readable Sequence Listing filed herewith are identical. Support for all the sequences listed in the Substitute Sequence Listing can be found in the present application. No new matter is believed to be introduced by the submission of the Substitute Sequence Listing and the computer-readable Sequence Listing.

In light of the above, Applicants respectfully submit that they have fully complied with the Notices dated January 29, 2002, and August 30, 2002. Therefore, Applicants submit that this application is in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

✓ James J. Kelly, Ph.D.  
Registration No.: 41,504



**22850**

(703) 413-3000  
Fax #: (703) 413-2220  
NFO/JK/TWB:twb:aps  
I:\atty\Twb\217365us-pr3.wpd